Press releases

Press release 2018/12/21 Regulatory

First patient with colorectal cancer dosed in the Phase ll study of birinapant in combination with Keytruda®

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient in the phase ll part of the...

Press release 2018/12/14 Regulatory

The transformation into a company focused on clinical development of pharmaceuticals has now been completed and Medivir gives a project update

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the transformation to focus the company’s internal resources on its...

Press release 2018/11/21

Medivir nominates MIV-828 as a candidate drug for the treatment of hematological malignancies

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that MIV-828 has been nominated as a candidate drug (CD) for...

Press release 2018/10/26 Regulatory

MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2018

July – SeptemberSignificant events during the quarter Positive top-line joint structure outcomes were reported from the MIV-711 osteoarthritis phase II extension...

Press release 2018/10/19

New data from the MIV-711 phase II program will be presented at the ACR Annual Meeting on October 21

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the initial phase II study of MIV-711,...

Press release 2018/10/17 Regulatory

Medivir scales back research costs to focus on clinical development

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced today plans to reduce activities not critical to its development pipeline of...

Press release 2018/10/15 Regulatory

Medivir to focus on its clinical development and appoints Uli Hacksell as acting CEO

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced today its plans to concentrate its activities on clinical development. As a...

Press release 2018/10/04 Regulatory

Positive interim data on birinapant in combination with Keytruda®

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced safety and efficacy data following an interim analysis of phase I...

Press release 2018/10/01 Regulatory

Phase I/II clinical study of MIV-818 started in patients with liver cancer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the first patient has been enrolled and dosed with MIV-818...

Press release 2018/09/10 Regulatory

Medivir appoints Dr. Linda Basse as Chief Medical Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Linda Basse as Chief Medical Officer effective October...

Press release 2018/08/02

Investigator-initiated phase II clinical study of remetinostat started in patients with basal cell carcinoma

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient has been enrolled and is being dosed...

Press release 2018/07/27 Regulatory

MIV-711 osteoarthritis phase IIa extension study outcomes show continuing positive effect on joint structure

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces positive top-line joint structure outcomes from the MIV-711 osteoarthritis phase IIa...